Johnson & Johnson Among Leading Companies in the Depression Pipeline Products Market | Globaldata Plc

June 23, 2022

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest

/EIN News/ -- LONDON, June 23, 2022 (GLOBE NEWSWIRE) -- Signs and symptoms of depression include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness, and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers, or antipsychotics.

Depression pipeline therapeutics constitute close to 333 molecules. Out of these approximately 310 molecules are developed by companies and remaining by the universities/institutes.

The Depression Drugs in Development market research report offered by GlobalData Plc provides comprehensive information on the therapeutics under development for depression (central nervous system), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Depression Pipeline Products Market Segmentation by Target

Depression Pipeline Products Market Analysis, by Targets

For more target insights, download a free report sample

Depression Pipeline Products Market Segmentation by Mechanisms of Action

Depression Pipeline Products Market Analysis, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Depression Pipeline Products Market Segmentation by Routes of Administration

Depression Pipeline Products Market Analysis, by Routes of Administration

For more routes of administration insights, download a free report sample

Depression Pipeline Products Market Segmentation by Molecule Types

Depression Pipeline Products Market Analysis, by Molecule Types

For more molecule type insights, download a free report sample

Leading Companies in the Depression Pipeline Products Market

Depression Pipeline Products Market, by Leading Companies

To know more about leading companies, download a free report sample

Depression Pipeline Products Market Overview

Targets 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, Sodium Dependent Noradrenaline Transporter, Glutamate Ionotropic Receptor AMPA Type Subunit, Sodium Dependent Dopamine Transporter, 5-Hydroxytryptamine Receptor 7, and D3 Dopamine Receptor
Mechanisms of Action 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Sodium Dependent Serotonin Transporter Inhibitor, D2 Dopamine Receptor Antagonist, Sodium Dependent Noradrenaline Transporter Inhibitor, D2 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Sodium Dependent Dopamine Transporter Inhibitor
Routes of Administration Oral, Intravenous, Sublingual, Subcutaneous, Nasal, Intramuscular, Buccal, Inhalational, Parenteral, and Transdermal
Molecule Types Small Molecule, Biologic, Peptide, Synthetic Peptide, Recombinant Protein, Antisense RNAi Oligonucleotide, Cell Therapy, and Protein
Leading Companies Johnson & Johnson, Luye Pharma Group Ltd, Shenox Pharmaceuticals LLC, MD Healthcare Inc, Atai Life Sciences NV, H. Lundbeck AS, Intra-Cellular Therapies Inc, Korea Pharma Co Ltd, Neurocrine Biosciences Inc, and Otsuka Pharmaceutical Co Ltd

Depression Pipeline Products Market Report Scope

Reasons to Buy

FAQs

What are the key targets in the depression pipeline products market?
The key targets of the depression pipeline products market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, Sodium Dependent Noradrenaline Transporter, Glutamate Ionotropic Receptor AMPA Type Subunit, Sodium Dependent Dopamine Transporter, 5-Hydroxytryptamine Receptor 7, and D3 Dopamine Receptor.

What are the key mechanisms of action in the depression pipeline products market?
Some of the key mechanisms of action of the depression pipeline products market are 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Sodium Dependent Serotonin Transporter Inhibitor, D2 Dopamine Receptor Antagonist, Sodium Dependent Noradrenaline Transporter Inhibitor, D2 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Sodium Dependent Dopamine Transporter Inhibitor.

What are the key routes of administration in the depression pipeline products market?
The key routes of administration in the depression pipeline products market are oral, intravenous, sublingual, subcutaneous, nasal, intramuscular, buccal, inhalational, parenteral, and transdermal.

What are the key molecule types in the depression pipeline products market?
The key molecule types in the depression pipeline products market are small molecule, biologic, peptide, synthetic peptide, recombinant protein, antisense RNAi oligonucleotide, cell therapy, and protein.

Which are the leading companies in the depression pipeline products market?
Some of the key companies in the depression pipeline products market are Johnson & Johnson, Luye Pharma Group Ltd, Shenox Pharmaceuticals LLC, MD Healthcare Inc, Atai Life Sciences NV, H. Lundbeck AS, Intra-Cellular Therapies Inc, Korea Pharma Co Ltd, Neurocrine Biosciences Inc, and Otsuka Pharmaceutical Co Ltd

Related Reports

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400